Three specialty semiconductor companies—Navitas Semiconductor, Alpha and Omega Semiconductor, and Tower Semiconductor—are positioned to benefit from AI infrastructure growth beyond the well-known megacaps. Navitas leads in 800V DC architecture for AI data centers with strong revenue growth and key partnerships, though its stock is highly valued and dependent on timing. Alpha and Omega offers a cheaper entry into AI/server power semiconductors with improving margins but remains unprofitable and faces some risks from consumer segment declines and supply disruptions. Tower Semiconductor, a specialty foundry focused on silicon photonics, shows robust profitability and large contracted revenue for 2027, though it carries execution and geopolitical risks. Investors should watch upcoming quarterly reports and AI infrastructure adoption timelines to gauge these companies' potential to attract broader market attention.
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings Inc and Omico have formed a partnership to accelerate precision oncology research in Australia by connecting cancer patients to biomarker-driven clinical trials. The collaboration combines Fortrea's expertise in oncology clinical tri...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
Fortrea Holdings Inc and Omico have formed a partnership to enhance precision oncology research in Australia by matching cancer patients with biomarker-driven clinical trials. This collaboration combines Fortrea's expertise in oncology clinical trial...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research by improving biomarker-based clinical trial planning and patient recruitment in Australia. The collaboration leverages Fortrea's clinical trial expertise a...
